Case report: Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 3, 1999, Pages 262-268

  Lau, George K K ^a   Yuen, Siu Tsan ^a   Au, Wing Yan ^a   Wu, Pui Chee ^a   Liang, Raymond ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Adoptive immunity transfer; Hepatitis B infection; Histology

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FAMCICLOVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; METHOTREXATE; 2 AMINOPURINE; ANTIVIRUS AGENT; DRUG DERIVATIVE;

ACUTE HEPATITIS; ADOLESCENT; ADOPTIVE TRANSFER; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC HEPATITIS; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; GRAFT VERSUS HOST REACTION; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER NECROSIS; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS CARRIER; VIRUS NEUTRALIZATION; BLOOD; BONE MARROW TRANSPLANTATION; LIVER; PATHOLOGY; VIROLOGY;

2-AMINOPURINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LIVER; MALE;

EID: 0033087125     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01845.x     Document Type: Article

References (33)

1. 1 Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by BMT from a hepatitis B immune donor. Gastroenterology 1993; 104: 1818-21.
2. 2 Lok ASF, Liang RH, Chung H. Recovery from hepatitis B (Letter). Ann. Intern. Med. 1992; 116: 957.
3. 3 Chen PM, Fan S, Liu CJ et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49: 708-13.
4. 4 Lau GKK, Lok ASF, Liang R et al. Clearance of HBsAg after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology 1997; 25: 1497-501.
5. 5 Lau GKK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Efficacy of famciclovir to prevent HBV reactivation in HBsAg positive recipients after allogeneic bone marrow transplantation. J. Hepatol. 1998; 28: 359-68.
6. 6 Urdea MS, Kolberg J, Warner BD et al. A novel method for the rapid detection of hepatitis B virus in human serum samples without blotting or radioactivity. In: Van Dyke K, ed. Luminescence Immnnoassay and Molecular Applications. Boston: CRC Press, 1990; 275-92.
7. 7 Chung HT, Lok ASF, Lai CL. Re-evaluation of α-interferon treatment of chronic hepatitis B using polymerase chain reaction. J. Hepatol 1993; 17: 208-14.
8. 8 Lau GKK, Davis GL, Wu PC, Gish R, Barlat LA, Lau JYN. Hepatic expression of hepatitis C virus in chronic hepatitis C: A study by in situ reverse transcription polymerase chain reaction. Hepatology 1996; 23: 1318-23.
9. 9 Jarvis LM, Davidson F, Hanley JP, Yap PL, Ludlam CA, Simmonds P. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348: 1352-5.
10. 10 Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
11. 11 Wu PC, Fang JWS, Lai CL, Lau SKH, Lo CK. Hepatic expression of hepatitis B virus genome in chronic hepatitis B virus infection. Am. J. Clin. Pathol. 1996; 105: 87-95.
12. 12 Mason DY, Cordell JL, Gaulard P, Tse AGD, Brown MH. Immunohistochemical detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence. J. Clin. Pathol. 1992; 45: 1084-8.
13. 13 Wands J, Chura C, Roll F, Maddrey W. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-12.
14. 14 Nagington J, Cossart Y, Cohen B. Reactivation of hepatitis B after transplantation operations. Lancet 1977; i: 558-60.
15. 15 Degas F, Lugassy C, Degott C et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology 1988; 94: 151-6.
16. 16 Chazouilleres O, Mamish D, Kim M et al. Occult hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142-6.
17. 17 Wachs M, Amend W, Ascher L et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 49: 230-4.
18. 18 Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-42.
19. 19 Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med. 1996; 10: 1104-8.
20. 20 Lok ASF, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
21. 21 Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B treated with interferon alpha. Gastroenterology 1993; 105: 1833-8.
22. 22 Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J. Hepatol. 1997; 27: 572-7.
23. 23 Hervas-Stubbs S, Lasarte JJ, Sarobe P et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J. Hepatol. 1997; 27: 726-37.
24. 24 Guidotti LG, Ando K, Hobbs MV et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci. USA 1994; 91: 3764-8.
25. 25 Chisari FV, Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 1997; 99: 1472-7.
26. 26 Rehermann B, Lau D, Hoofnagle JH, Chisari F. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 1996; 97: 1655-65.
27. 27 Cerny A, Fowler P, Brothers MA, Houghton M, Schlicht HJ, Chisari FV. Induction in vitro of a primary human antiviral cytotoxicT cell response. Eur. J. Immunol. 1995; 25: 627-30.
28. 28 Ferrari C, Bertoletti A, Penna A et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J. Clin. Invest. 1991; 88: 214-22.
29. 29 Heathcote J, McHutchison K, Benner T et al. CY-1899: A therapeutic vaccine for chronic hepatitis B. Hepatology 1996; 24: 283A.
30. 30 Pol S. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994; 344: 342 (Letter).
31. 31 Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as an approach for vaccine therapy. Lancet 1995; 345: 1575-6.
32. 32 Shaw T, Amor G, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 1994; 38: 719-23.
33. 33 Trepo C, Jezek P, Atkinson GF, Boon RJ. Long term efficacy of famciclovir (FVC) in chronic hepatitis B: Results of a phase IIB study. J. Hepatol 1997; 26 (Suppl. 1): 74.